DUBLIN, Ohio, May 14, 2019 /PRNewswire/ — Cordis, a Cardinal Health company, recently announced the full U.S. launch of its RADIAL 360 portfolio, offering a complete range of products to facilitate the transradial approach (TRA) for interventional cardiology procedures. The transradial approach uses the radial artery in the wrist to access the body’s […]
Other News
Eximo Medical Ltd. Announces the First Successful Use of the B-Laser™ Atherectomy System in Crossing Chronic Total Occlusion (CTO) without a guidewire
REHOVOT, Israel–(BUSINESS WIRE)–Eximo Medical Ltd., announced today the first successful use of the B-Laser™Atherectomy System in a “step-by-step” approach (crossing a non-crossable CTO cap without guidewire) for the therapy of patients afflicted by highly complex, arterial occlusive peripheral arterial disease (PAD) as well as the first ever utilization of On-line Photo-Acoustic Monitoring […]
Balt USA, LLC Announces CE Mark Obtained for Titan™ Aspiration Catheter
IRVINE, Calif.–(BUSINESS WIRE)–Balt USA, LLC announces today it has obtained CE mark for the Titan aspiration catheter. The Titan catheter line consists of a highly navigable, large bore (.070”) aspiration catheter and a smaller bore (.036”) catheter for navigation and support. Obtaining the CE mark for Titan* enhances the Balt stroke […]
Ra Medical Systems Reports First Quarter 2019 Financial Results
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2019 and provides a business update. Recent Operational Highlights Submitted an Investigational Device Exemption (IDE) to the […]
Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan
ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO® (esaxerenone) tablets as a treatment for patients with hypertension in Japan. With Daiichi Sankyo’s first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under […]
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ:ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The expansion extends the duration of support for each pump from 6 days to 14 days. The Impella 5.0 and the Impella LD are forward flow heart pumps […]
FDA Grants First Ever Clearance For Six-Lead Personal ECG Device
MOUNTAIN VIEW, Calif., May 13, 2019 /PRNewswire/ — AliveCor, the leader in FDA-cleared consumer electrocardiogram technology (ECG), today announced its third FDA clearance in three months, making KardiaMobile 6L the world’s first available six-lead personal ECG device. This highly anticipated clearance gives patients and their physicians an even more detailed view into patients’ […]
MyoKardia Reports First Quarter 2019 Financial Resul
Announces Enrollment Completing in the Phase 2 MAVERICK-HCM Trial Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment […]
NEW STUDIES HIGHLIGHT UNDERUSE OF IMPLANTABLE CARDIAC DEVICES
DUBLIN and SAN FRANCISCO – May 10, 2019 – Three new studies show that patients who are medically indicated for implantable heart devices, including implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT), often do not receive needed therapy. The findings underscore gender and race treatment disparities, as well as a […]
Quantum Genomics Announces the Publication of a New Scientific Article in the Journal Hypertension
PARIS and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces the publication of a new scientific article in the […]



